Solventum Corporation (NYSE:SOLV) Receives $90.64 Consensus Price Target from Analysts

Shares of Solventum Corporation (NYSE:SOLV) have received an average recommendation of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $90.6364.

Several equities analysts have issued reports on the company. BTIG Research reiterated a “buy” rating and set a $100.00 target price on shares of Solventum in a research report on Friday, February 27th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Piper Sandler reissued an “overweight” rating on shares of Solventum in a research note on Wednesday, December 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Finally, KeyCorp boosted their price target on Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a research note on Friday, February 27th.

Insider Activity at Solventum

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, with a total value of $100,344.25. Following the purchase, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. The trade was a 41.39% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is owned by company insiders.

Institutional Investors Weigh In On Solventum

Several institutional investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Solventum by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after acquiring an additional 867,837 shares in the last quarter. Independent Franchise Partners LLP lifted its stake in Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock valued at $1,216,785,000 after buying an additional 2,456,451 shares in the last quarter. State Street Corp lifted its stake in Solventum by 2.0% in the 4th quarter. State Street Corp now owns 6,344,761 shares of the company’s stock valued at $502,759,000 after buying an additional 124,490 shares in the last quarter. Davis Selected Advisers lifted its stake in Solventum by 12.7% in the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock valued at $492,880,000 after buying an additional 702,461 shares in the last quarter. Finally, Boston Partners lifted its stake in Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares in the last quarter.

Solventum Stock Performance

NYSE SOLV opened at $62.49 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The business’s 50 day moving average is $70.88 and its two-hundred day moving average is $75.03. Solventum has a 12-month low of $60.70 and a 12-month high of $88.20. The stock has a market capitalization of $10.84 billion, a price-to-earnings ratio of 7.04, a PEG ratio of 1.04 and a beta of 0.71.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, February 26th. The company reported $1.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The company had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter in the previous year, the firm posted $1.41 EPS. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Research analysts expect that Solventum will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.